Corcept Therapeutics (NASDAQ:CORT) Insider Sean Maduck Sells 20,000 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 20,000 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $73.99, for a total value of $1,479,800.00. Following the completion of the transaction, the insider owned 7,904 shares in the company, valued at $584,816.96. The trade was a 71.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Sean Maduck also recently made the following trade(s):

• On Wednesday, October 1st, Sean Maduck sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $85.06, for a total value of $1,701,200.00.
• On Tuesday, September 2nd, Sean Maduck sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $70.49, for a total value of $1,409,800.00.

Corcept Therapeutics Stock Up 7.8%

Corcept Therapeutics stock opened at $76.65 on Thursday. The stock has a market cap of $8.08 billion, a price-to-earnings ratio of 67.83 and a beta of 0.43. Corcept Therapeutics Incorporated has a 12-month low of $49.00 and a 12-month high of $117.33. The business’s 50-day simple moving average is $76.68 and its 200 day simple moving average is $73.40.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.02). The business had revenue of $207.64 million during the quarter, compared to the consensus estimate of $223.78 million. Corcept Therapeutics had a net margin of 18.51% and a return on equity of 20.10%. The firm’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period last year, the business posted $0.41 EPS. Corcept Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Corcept Therapeutics in a research note on Monday, October 20th. Wall Street Zen cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, October 18th. Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 1st. Piper Sandler reduced their price objective on shares of Corcept Therapeutics from $131.00 to $121.00 and set an “overweight” rating on the stock in a research note on Friday, August 1st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $135.25.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its position in Corcept Therapeutics by 24.5% in the 1st quarter. Victory Capital Management Inc. now owns 93,418 shares of the biotechnology company’s stock valued at $10,670,000 after acquiring an additional 18,389 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its position in Corcept Therapeutics by 883.0% in the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 19,660 shares of the biotechnology company’s stock valued at $1,443,000 after acquiring an additional 17,660 shares in the last quarter. Voya Investment Management LLC lifted its holdings in shares of Corcept Therapeutics by 5.3% in the first quarter. Voya Investment Management LLC now owns 234,648 shares of the biotechnology company’s stock valued at $26,801,000 after purchasing an additional 11,898 shares in the last quarter. Iron Gate Global Advisors LLC bought a new stake in shares of Corcept Therapeutics in the first quarter valued at about $400,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Corcept Therapeutics by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,353 shares of the biotechnology company’s stock valued at $6,437,000 after purchasing an additional 10,320 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.